ERBB2 and maternal uniparental disomy of chromosome 20: First-line therapy selection in HER2-negative MBCs was conducted either based on the CTC quantity by CellSearch where patients with <5 CTCs per 7.5 mL blood were treated with endocrine therapy, while those with ≥5 CTCs with chemotherapy or by clinicians’ choice without knowing the CTC counts.